Clinical Trial

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

Study acronym: SPARK
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-10-07; most recent amendment 2025-10-15.
Status change: Not Yet Recruiting → Recruiting 2025-10-15
Trial Details
NCT Number NCT06632379
Lead Sponsor Ohio State University
Conditions Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Enrollment 76 participants
Start Date 2025-10-03
Primary Completion 2026-09-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-10-20